secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0000950170-24-032162
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences appoints Gilead designee to board, adopts 2024 bonus plan
------------------------------------------------------------------------------

- Robert D. Cook II, Gilead's VP of Risk Governance and Audit, appointed to Board as Gilead designee per Oct 15, 2023 Investor Rights Agreement; no compensation.
- Compensation Committee approved 2024 Corporate Bonus Plan effective Jan 1 2024 with cash bonuses tied to corporate and individual objectives.
- CEO bonus target up to 75% of base salary; other executive participants 30-55%; non-executive participants up to 28%.
- Cash bonuses range from 0 to 1.5x target; paid by March 15 following performance year; employment through payment date required.
- Weighting: CEO 100% corporate; C-Level/SVP 75/25; VP/Exec Dir/Sr Dir 50/50; below Sr Dir 25/75.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024032162/0000950170-24-032162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024032162/asmb-20240312.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-032162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer